British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

FTSE 100 reaction as HSBC sees profits drop, Nationwide launches benefits line - Stock market news and latest business and ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...